TY  - JOUR
AU  - Martínez-Cuadrón, David
AU  - Boluda, Blanca
AU  - Martínez, Pilar
AU  - Bergua, Juan
AU  - Rodríguez-Veiga, Rebeca
AU  - Esteve, Jordi
AU  - Vives, Susana
AU  - Serrano, Josefina
AU  - Vidriales, Belen
AU  - Salamero, Olga
AU  - Cordón, Lourdes
AU  - Sempere, Amparo
AU  - Jiménez-Ubieto, Ana
AU  - Prieto-Delgado, Julio
AU  - Díaz-Beyá, Marina
AU  - Garrido, Ana
AU  - Benavente, Celina
AU  - Pérez-Simón, José Antonio
AU  - Moscardó, Federico
AU  - Sanz, Miguel A
AU  - Montesinos, Pau
AU  - CETLAM and PETHEMA groups
PY  - 2018
DO  - 10.1007/s00277-018-3277-x
UR  - http://hdl.handle.net/10668/12172
T2  - Annals of hematology
AB  - The name of Pau Montesinos was inadvertently presented as Pau Montesinos Fernández in the original article.The original version of this article was revised: The name of Pau Montesinos was inadvertently presented as Pau Montesinos Fernández.
LA  - en
TI  - Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
TY  - research article
VL  - 97
ER  -